|Bid||105.01 x 800|
|Ask||115.64 x 900|
|Day's Range||105.40 - 109.60|
|52 Week Range||51.05 - 133.74|
|Beta (3Y Monthly)||2.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||138.78|
At a time when other social networking sites like Facebook (NASDAQ:FB) are struggling to figure out their place in the foreseeable future, Twitter (NYSE:TWTR) is enjoying the fact that it has just recently figured out what it is and how to sell itself. The pros are calling for sales growth of nearly 14% next year, though, which should drive the bottom line up to 89 cents per share of TWTR stock. The trading crowd hasn’t exactly priced Twitter shares like the growth machine it is.
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...
Investors need to pay close attention to Intercept Pharmaceuticals (ICPT) stock based on the movements in the options market lately.
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
On November 28, Acadia Pharmaceuticals (ACAD) stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27. On November 27, Acadia Pharmaceuticals announced a price of $17.00 per share for an underwritten public offering of 16,176,471 shares of its common stock. Acadia Pharmaceuticals’ net revenue in the first nine months of the year amounted to $164.2 million compared to $81.3 million in the same period last year.
NEW YORK, NY / ACCESSWIRE / November 29, 2018 / Wall Street closed up on Wednesday as dovish comments made by Federal Reserve Chairman Jerome Powell boosted investor optimism. According to the Chairman, Jerome Powell, “Interest rates are still low by historical standards, and they remain just below the broad range of estimates of the level that would be neutral for the economy — that is, neither speeding up nor slowing down growth.” The Dow Jones Industrial Average surged 2.5 percent to close at 25,366.43, while the S&P 500 Index jumped 2.3 percent to close at 2,743.79. “Markets wanted to hear Powell say that there is no preset course of rates, that he is mindful of weaknesses in the global economy, and, most importantly, that tariffs have altered the calculus of the future of the U.S. economy,” Cox said.
President & CEO of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Mark Pruzanski sold 50,000 shares of ICPT on 11/16/2018 at an average price of $101.07 a share.
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / U.S. equities regained footing on Thursday as oil prices climbed and hopes of a trade agreement between the U.S. and China raised investor’s optimism. The ...
Pharma stocks can serve as a profitable addition to investment portfolios. With 10,000 baby boomers aging into Medicare every day, and a Medicare Part D drug plan to subsidize the cost, demographics and government subsidies has created a virtuous cycle for healthcare stocks. As a result, some have seen price levels that its profits (assuming they exist) cannot sustain. Additionally, biotech stocks are inherently risky due to the process of drug development and approval.
NEW YORK, NY / ACCESSWIRE / November 8, 2018 / U.S. markets advanced on Wednesday as the midterm election results went according to market expectations. The Democrats took over the House, while the Republicans ...
Intercept (ICPT) delivered earnings and revenue surprises of 17.74% and 0.76%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The New York-based company said it had a loss of $2.18 per share. The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of ...
Intercept Pharmaceuticals Inc. shares rose 3.2% in Wednesday premarket trade after the company reported a narrower-than-expected third-quarter loss. Intercept Pharma reported a net loss of $64.5 million, or a loss of $2.18 per share, after a loss of $72.6 million, or a loss of $2.89 per share in the year-earlier period. The FactSet adjusted earnings-per-share consensus was a loss of $2.56. Revenue rose to $46.99 million from $41.33 million, compared with the FactSet consensus of $48.2 million. Ocaliva sales rose to $46.6 million from $40.9 million, below the FactSet consensus of $47 million. Intercept Pharma still expects early results from its phase 3 trial testing Ocaliva in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) in the first half of next year. The company continues to expect 2018 net sales for its Ocaliva therapy of between $170 million and $185 million, in line with the FactSet consensus of $177.8 million. Intercept shares have dropped 4.3% over the last three months, compared with a 4.8% drop in the S&P 500 and a 2.1% decline in the Dow Jones Industrial Average .
Worldwide Ocaliva net sales of $46.6 million in the third quarter of 2018Leading Phase 3 NASH program continues to advance: REGENERATE trial in NASH patients with advanced liver.
Short interest is moderately high for ICPT with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on October 25.